Multiple Sclerosis (MS) access in Oman: the MoH-DGPADC named-patient pathway

Creator: Reserve Meds
Published: 2026-05-18

How patients in the Sultanate of Oman with MS legally obtain US-sourced FDA-labelled therapies when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.

Last reviewed 2026-05-18 by Reserve Meds clinical and regulatory team.

Quick orientation

Patients in Oman with Multiple Sclerosis (MS) access US-sourced specialty therapies through the MoH-DGPADC named-patient pathway, a the Directorate General of Pharmaceutical Affairs and Drug Control of the Oman Ministry of Health-administered mechanism that allows a Omani-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the global epidemiology of MS, the treatment options that typically travel through the cross-border route, real-world timelines, and the cost band in OMR terms.

Reserved for you.

Epidemiology and clinical context of Multiple Sclerosis (MS)

Multiple sclerosis is a chronic immune-mediated demyelinating disease of the central nervous system. Global prevalence is estimated at 2.8 million cases; female-to-male ratio is approximately 3:1. Phenotypes include relapsing-remitting (most common at diagnosis), secondary-progressive, and primary-progressive. A broad set of disease-modifying therapies has substantially altered the natural history of relapsing disease.

Global prevalence is in the range of approximately 35-100 per 100,000 globally; sharply higher in temperate latitudes. ICD-10 classifies the condition under G35. The clinical picture in Oman reflects the same biological substrate, though referral patterns, age at diagnosis, and access to specialised diagnostic centres vary by region.

Why Omani families pursue the named-patient route for MS

the Sultanate of Oman operates a structured pharmaceutical regulatory environment. Modern MS therapy is regulated through MoH-DGPADC channels, and a Omani family seeking cross-border supply is rarely asking for a treatment that does not exist locally. They are usually asking for a precise version of it that the local market has not caught up to.

Four converging patterns drive these cases. First, indication lag - newer FDA-approved indications and dosing expansions for MS therapies reach local registration 12 to 36 months after the US label. Second, presentation gaps - the exact strength, weight-banded dose, pediatric vial size, or device format the prescriber requires may not be stocked at the local agent even when the medicine is registered. Third, payer denial - the MoH public coverage, the National Life and General Insurance Company (NLIC), Oman Insurance (Sukoon), and AXA Gulf Oman employer plans each assess specialty therapies case by case, and step-therapy or formulary rules often produce denials even when the drug is on the local register; cash-pay families pursue cross-border supply rather than wait through appeals. Fourth, continuity of supply - when a US-stable patient relocates to Oman or visits family for an extended period, maintaining the original FDA-sourced regimen matters more than switching to a different local presentation.

In each pattern, the MoH-DGPADC named-patient pathway is the mechanism that connects a Omani-licensed physician's clinical decision with US-sourced, FDA-labeled product for a specific patient.

The MoH-DGPADC named-patient pathway in detail

The pathway for a Omani-licensed physician to obtain a medicine that is not registered or not stocked locally is the named-patient import authorisation administered by the Directorate General of Pharmaceutical Affairs and Drug Control (DGPADC) of the Oman Ministry of Health, which allows a treating physician at a registered MoH facility or licensed private hospital to apply for the import of an unregistered medicine for a specific named patient where the medicine is approved by a recognised reference authority. The framework allows registered healthcare facilities to import a specific medicine for a specific patient when the medicine is approved by a recognised reference authority (typically the US FDA, EMA, MHRA, PMDA Japan, or Health Canada) and a clinically equivalent locally registered alternative is not suitable.

For MS, the clinical justification typically frames the case around relapsing-remitting and active secondary-progressive MS; primary-progressive MS (ocrelizumab); high-efficacy escalation. A complete application includes a clinical justification letter from the treating physician (diagnosis with confirmatory genetic or biomarker testing where relevant, severity scores, prior therapies and their outcomes, why this specific drug, why the locally stocked option is not suitable), the treating physician's Omani medical license verification through the Oman Medical Specialty Board (OMSB) and the MoH DGPADC, an anonymised patient identifier where the MoH-DGPADC submission allows, full product details (brand name, generic name, manufacturer, strength, dosage form, pack size, quantity requested, intended treatment duration), the destination dispensing facility name, license number, and pharmacy in charge, and a chain-of-custody plan describing how the medicine will move from the US manufacturer through the importer to the dispensing pharmacy.

Approval timelines for routine cases are typically 10 to 25 business days. Complex cases (rare indication, larger quantities, first import of a given pediatric or weight-banded format, ultra-cold cell and gene therapies) can extend to 5 to 8 weeks. MoH-DGPADC retains discretion on timing, and we do not promise specific durations.

Treatment options that travel through the MoH-DGPADC route for MS

Modern disease-modifying or symptomatic therapy for MS spans a small set of brand-name products, most of which originate from US-headquartered or US-licensed manufacturers and reach the FDA-approved label before equivalent registration in Oman. The list below captures the products most frequently requested by Omani specialists through the named-patient route. Each links to its drug-specific access page on Reserve Meds with regulatory, logistics, and cost detail.

Ocrevus (ocrelizumab) is an anti-CD20 monoclonal antibody approved for both relapsing forms and primary-progressive MS.
Kesimpta (ofatumumab) is a subcutaneous anti-CD20 monoclonal antibody for relapsing forms of MS.
Tysabri (natalizumab) is an alpha-4 integrin antagonist for relapsing MS with JCV-stratified PML risk monitoring.
Mavenclad (cladribine) is an oral selective lymphocyte-depleting agent administered in two short annual courses.

Choice of therapy depends on the patient's full phenotype, genotype where relevant, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not substitute, advise on substitution, or promote one brand over another.

Real cost band for MS in Oman

Modern MS therapies span a wide cost spectrum, from small-molecule oral therapies in the four- to five-figure annual US-WAC range to one-time gene therapies above USD one million per administration. The firm quote we send back includes the exact drug-cost line for the prescribed regimen against current manufacturer list pricing (Roche, Novartis, Sanofi, Pfizer, BioMarin, Sarepta, Vertex, Bluebird Bio, BioMarin, CSL, Bayer, Lilly, or others as applicable). The OMR conversion is calculated at the prevailing rate on the day of quote issue.

International logistics for shipment to Oman typically runs USD 400 to USD 1,500 depending on destination city, urgency, and presentation: cold-chain biologics and gene therapies carry the higher end of the range; ambient oral solids the lower. the Sultanate of Oman customs and MoH-DGPADC permit fees are nominal relative to drug cost. Reserve Meds' concierge fee is itemised separately on every firm quote.

On the insurance side, the MoH public coverage, the National Life and General Insurance Company (NLIC), Oman Insurance (Sukoon), and AXA Gulf Oman employer plans each assess named-patient imports case by case. Some reimburse fully when the medicine is on their formulary even if not stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We do not promise coverage from any insurer. US manufacturer copay cards and patient assistance programs do not extend internationally; cross-border patients pay cash or rely on local payer coverage.

Where MS therapies get dispensed in Oman

A small group of Omani institutions handle named-patient imports for rare and specialty conditions as established workflow, with in-house import pharmacy infrastructure and physicians experienced with the application set. Tertiary and major private hospitals that meet this profile include Sultan Qaboos University Hospital in Muscat, the Royal Hospital in Muscat, Khoula Hospital in Muscat, the National Oncology Centre at the Royal Hospital, and Muscat Private Hospital. Each maintains pharmacy infrastructure appropriate to the relevant presentation (2 to 8 degrees Celsius cold-chain for biologics, ultra-cold or specialised handling for cell and gene therapies, ambient storage for oral therapies).

For physicians at smaller hospitals without internal import infrastructure, the common pattern is to route through a specialty importer that holds a pharmaceutical establishment license and files the MoH-DGPADC application on the prescribing physician's behalf. The medicine then moves into the prescribing hospital's outpatient or specialty pharmacy under chain-of-custody documentation. For one-time cell and gene therapies in particular, the dispensing facility must demonstrate qualified storage, documented temperature monitoring, infusion or apheresis capability where applicable, and a chain-of-custody record that meets the manufacturer's risk-evaluation-and-mitigation expectations.

Common questions about MS access in Oman

Is MS treated through the MoH-DGPADC named-patient pathway in Oman?

Yes. When the prescribing Omani specialist documents that a specific MS therapy is not registered or not stocked in Oman, the MoH-DGPADC pathway provides the regulatory mechanism to import the FDA-approved product for a specific named patient. the named-patient import authorisation administered by the Directorate General of Pharmaceutical Affairs and Drug Control (DGPADC) of the Oman Ministry of Health.

How long does MoH-DGPADC approval typically take?

Routine cases run 10 to 25 business days from a complete filing. Complex cases (rare indication, first import of a pediatric or weight-banded format, larger quantities) can extend to 5 to 8 weeks. MoH-DGPADC retains discretion on timing; Reserve Meds does not promise specific durations.

What does MS treatment cost in Oman?

The drug-cost line tracks US wholesale acquisition cost (WAC) for the prescribed product; the firm quote we send back includes the exact figure against current manufacturer list pricing. International logistics into Oman typically runs USD 400 to USD 1,500 depending on destination city, urgency, and cold-chain requirements. MoH-DGPADC permit fees are nominal relative to drug cost. The Reserve Meds concierge fee is itemised separately on every firm quote.

Will the MoH public coverage cover this?

Each insurer assesses named-patient imports case by case. Some the MoH public coverage, the National Life and General Insurance Company (NLIC), Oman Insurance (Sukoon), and AXA Gulf Oman employer plans reimburse fully when the medicine is on the formulary even if not stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We supply the documentation set that lets your insurer assess the case; the claim sits with you or your hospital.

Which Omani hospitals dispense Ocrevus and similar specialty therapies?

Tertiary and major private hospitals that maintain in-house import pharmacy infrastructure include Sultan Qaboos University Hospital in Muscat, the Royal Hospital in Muscat, Khoula Hospital in Muscat, the National Oncology Centre at the Royal Hospital, and Muscat Private Hospital. Each operates pharmacy storage appropriate to the relevant presentation (2 to 8 degrees Celsius cold-chain for biologics, ultra-cold for select cell and gene therapies, ambient storage for oral therapies).

Where Reserve Meds fits in MS cases in Oman

Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace MoH-DGPADC, and we do not replace your dispensing pharmacy. For MS cases specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it, ultra-cold handling for relevant cell and gene therapies) into Oman, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies.

A typical MS case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing or administration plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the MoH-DGPADC application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks run in parallel, not in series; that is the operational difference between a 3-week and a 9-week case.

Next step

If your Omani physician is treating MS and is weighing the cross-border route for a specific FDA-approved therapy, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.

Start your case WhatsApp